1. Investigational new drugs: FDA's expanded access program : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives Publication: Washington, D.C. : U.S. Government Accountability Office, October 3, 2017 Subject(s): Drug Approval -- statistics & numerical dataDrugs, Investigational -- therapeutic useHealth Services AccessibilityPatient SafetyInvestigational New Drug ApplicationHumansUnited StatesUnited States. Food and Drug Administration.
